【参】六角形画像(Vision)
H1

Our Goal

コンテンツ

Top Message

We are pleased to announce that our new website is launched from today, May 31, 2019.  In order to achieve our goal, a new growth stage called as "GTS 3.0", which has been initiated since 2018, we are making concerted effort as one team, and as part of that, our website is also redesigned to convey our messages more simply and clearly.

 

Since the company was founded spun out from Hokkaido University in March 2001, we have been developing a hybrid business system for the past 18 years, which pursues a high business growth with new biologics business and regenerative medicine (cell therapy) business while stabilizing the business foundation in the biosimilar business.  Now our biosimilar business comes at the steady growth stage with pipelines that will be launched in the early 2020’s, following our first biosimilar product, Filgrastim BS, launched in 2013.  And, in order to realize "GTS 3.0" from now on, we will work on the research and development of new pharmaceuticals and therapeutic solutions in new biologics and regenerative medicine (cell therapy) businesses by leveraging know-how and expertise regarding biotechnology acquired in the biosimilar business.

 

Declining birthrate and the aging population become a serious social issue not only in Japan but also developed countries in the world.  Under this situation, we would like to contribute to healthcare with the therapeutic treatment for realizing the brighter future for children through our new biologics and regenerative medicine (cell therapy) businesses.  Unfortunately, it is the fact that research and development for pediatric diseases have not been active in this industry, and therefore, we think it truly important to support those children and juvenile people to be able to live healthier and higher quality of life.  In “GTS 3.0”, we will strive to fulfill innovative transformation and pursue much higher growth to realize such vision.

 

We would appreciate your continued support! 

Gene Techno Science
President & CEO
Masaharu Tani

Leadership Team to lead and execute GTS3.0 toward the success

コンテンツ

GTS3.0

Biotech Engineering Company, striving for value creation

Aiming at providing comprehensive healthcare solutions for patients as well as families and caregivers

Founded as a spin-out venture from Hokkaido University
Engaged in the research and development of new biologics and biosimilar products, and now striving for a new stage with cell therapy business

Start-up, IPO, Business Expansion

From Now On

For the Future

For the Future

Connecting advanced biotehcnologies existing in Japan,
and contributing to the brighter future for chirdren

Business Direction

Targeting diseases which has less accessibility for sufficient medical treatment, and exploring the new therapeutic area

Target Area

Pediatric disease (Including juvenile one), Orphan disease, Intractable disease, Asia-endemic disease

Our Mission

By applying the sophisticated biotechnologies

By applying the sophisticated biotechnologies, developing
credible products and services are essential for GTS to contribute to society across the world.

Brighter future for children

Declining birthrate and the aging population becomes a social
issue all over the world. It is no doubt that children and young people will be the generation to create next society. Important thing is for those young people to be able to live healthier and higher quality of life. Brighter future for children with our biotechnoloigies